Recently, Xinkainuo Medical Company announced the completion of 100 million yuan financing, jointly invested by Zhangjiang Hi-Tech, Pudong Capital, Zhangjiang Haoheng and Suxin Venture Capital. This round of financing will be used to accelerate the development of domestic and foreign markets and the deep cultivation of regions, while accelerating the layout of new products for neurological intervention and peripheral intervention.
Xinkainuo Medical Technology (Shanghai) Co., Ltd. was established in August 2014. It is a high-tech enterprise focusing on independent research and development and manufacturing of high-end implantable/interventional medical devices for nerves and peripheral blood vessels. It is committed to providing vascular implants for doctors and patients. / Interventional Device Solutions. The company is located in the International Medical Park of Zhangjiang Science City. It has an area of about 3,000 square meters including R&D, production and office space. It has a solid core management team, all of whom are from famous medical device companies at home and abroad. They have profound R&D and management experience. The average working experience is in more than fifteen years.
Xinkainuo attaches great importance to R & D and innovation, and has built a R & D system with independent R & D as the core. So far, it has formed a complete industrial layout dominated by nerve intervention and focused on peripheral vascular intervention.
In 2022, several products of the company have achieved progress, and the clinical enrollment of the new generation of SkyVega® blood flow directing dense mesh stent with innovative anti-thrombotic coating design has come to a perfect conclusion; the self-developed SkyFlow® intracranial thrombectomy stent, SkyLoach® cranial Products such as the inner balloon dilatation catheter and the SkySurfer® distal access catheter have obtained high-tech achievement transformation projects; peripheral interventional vascular stents have completed follow-up visits; the company’s business has covered 29 domestic provinces and regions; it has been certified for sales in many overseas countries.
Zhao Zhenxin, the founder and chairman of Xinkainuo Medical, said: “First of all, I would like to thank Zhangjiang Hi-Tech, Pudong Capital, Zhangjiang Haoheng and Suxin Venture Capital for their recognition and investment in Xinkainuo. Xinkainuo Medical insists on technological innovation and is listed. The complete series of cerebral ischemia thrombectomy products have been highly recognized by clinicians and have brought excellent therapeutic effects to stroke patients. We will accelerate the research and development of innovative cerebral hemorrhage and peripheral vascular interventional products, and at the same time accelerate the commercialization of the company’s products , provide high-quality products to more domestic and foreign users and patients, and continue to create greater value.”
Zhangjiang Hi-Tech said: “Sinkainuo is based on the fertile ground of innovation in Zhangjiang Science City, and is rapidly growing into an innovative device company serving the world. Sinkainuo’s product design concept is unique, continuous improvement ability is strong, clinical treatment effect is good, and clinical use experience is good. , Gradually meet the actual clinical needs of stroke patients with low penetration rate of basic treatment and few solutions for patients with peripheral vascular diseases. We are optimistic about the efficient R&D clinical registration team of Xinkainuo, expecting the products to cover a wider area, and looking forward to Xinkainuo Always be clinically oriented, use research and development to drive product enhancement, and contribute to the treatment of acute and chronic neurological and peripheral diseases.”
Pudong Capital said: “Sinkainuo is an innovative medical device company based in Pudong and looking at the world. The products of Sinkainuo have the concept and patent of domestic independent innovation design, the clinical treatment effect is good, and the clinicians and patients are highly recognized. As a Pudong As the manager of the state-owned fund of funds in the New Area, we will continue to fully empower and support independent innovation companies like Xinkainuo to cultivate, develop, and grow bigger and stronger in Pudong.”
Zhang Jiang Haoheng said: “The aging population and the rejuvenation of cardiovascular and cerebrovascular diseases have promoted the rapid growth of the neurological and peripheral interventional market. Xinkainuo is benchmarking against world-class neurological and peripheral interventional device companies, and is committed to providing clinically integrated neurological and peripheral interventional devices. Peripheral interventional surgery solutions. Several products of the company have been approved for marketing in China and the European Union, and the clinical treatment effect has been highly recognized by doctors and patients. The products under research are leading domestically in terms of design concepts and research and development progress. We are honored to participate in this round of the company Financing will help the company’s future development, and we look forward to launching more and better products of Xinkainuo as soon as possible to benefit patients.”
Suxin Venture Capital said: “The neurological intervention and peripheral vascular intervention industry in which Xinkainuo is located has a broad market space, and the trend of localization substitution is obvious. The company started to deploy in the industry very early, with a rich product pipeline, and each product is in the subdivided industry. The company has a strong first-mover advantage and technological advantages. The company’s R&D team is pragmatic and efficient. Under the leadership of Mr. Zhao, it completed a R&D pipeline comparable to many listed companies in a short period of time and with less R&D investment. The company In the next few years, many blockbuster products will be certified and put on the market. We are optimistic about the company’s continuous research and development capabilities, and believe that as more products are certified and put on the market, the company’s performance can achieve rapid growth in the next few years.”
attached
To view more project information, please go to “Smart Beast Analysis” .
media reports
Arterial Network Arterial Network Yiou Pioneering State
related events
- “Xinkainuo” completed 100 million yuan in financing, jointly invested by Zhangjiang Hi-Tech, Pudong Capital, Zhangjiang Haoheng and Suxin Venture Capital 2022-12-30
- Focusing on neurological intervention and peripheral intervention, “ Xinkainuo Medical” completed nearly 100 million yuan in round B financing2021-01-20
This article is transferred from: https://readhub.cn/topic/8m9VWz1IF8K
This site is only for collection, and the copyright belongs to the original author.